International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com),
a California-based stem cell therapeutics company, today announced that
the Company has been invited to present at the 5th
Annual Roth Capital Partners Institutional Investor Conference to be
held at the Westin New York at Times Square.
ISCO is scheduled to present on Wednesday, September 5, 2007 at 3:00
p.m. Eastern time. ISCO Chairman Kenneth Aldrich and CEO Jeff Krstich
will represent the company.
The Roth Conference, the largest of its kind in the nation, is expected
to attract over 1200 institutional investors or buyside attendees.
Interested parties can access a live audio web cast of this presentation
at http://www.wsw.com/webcast/roth13/stemcell/ .
A replay of this presentation will be available at the same location.
About International Stem Cell Corporation:
International Stem Cell is a biotechnology company currently focused on
developing therapeutic and research products. In the area of therapeutic
product development, ISCO's objective is to
create an unlimited source of human cells for use in the treatment of
several diseases, including diabetes, liver disease and retinal disease
through cell transplant therapy. In furtherance of this objective, ISCO
has developed pluripotent human stem cells from unfertilized human eggs,
and techniques to cause those stem cells to be "differentiated"
into the specific cell types required for transplant. It has developed
manufacturing protocols to produce the cells minimizing contamination
with animal by-products, a characteristic likely to be important in
meeting U.S. Food and Drug Administration requirements. ISCO also
provides the specialized cells and growth media needed for therapeutic
cell transplantation research to academic and commercial researchers in
related fields. For more information, visit the ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 Forward-Looking Statements Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements. |